Image

    5α-Reductase Inhibitors in Men Aged 50 Years or Older with Androgenetic Alopecia: A Retrospective Study

    Min H. Kang, Joong Sub Choi, Woo-Young Sim, Bark-Lynn Lew
    Studysummary This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Long-Term Efficacy and Safety of the Dual 5-Alpha Reductase Blocker Dutasteride on Male Androgenetic Alopecia Patients Journal of Dermatology · 2016
    2. Five-Year Efficacy of Finasteride in 801 Japanese Men with Androgenetic Alopecia Journal of Dermatology · 2015
    3. Global Photographic Assessment of Men Aged 18 to 60 Years with Male Pattern Hair Loss Receiving Finasteride 1 mg or Placebo Journal of The American Academy of Dermatology · 2012
    4. Finasteride and Sexual Side Effects Indian Dermatology Online Journal · 2012
    5. Finasteride, 1 Mg Daily Administration on Male Androgenetic Alopecia in Different Age Groups: 10-Year Follow-Up Dermatologic Therapy · 2011

    Related research 4

    1. Change in Hair Growth-Related Gene Expression Profile in Human Isolated Hair Follicles Induced by 5-Alpha Reductase Inhibitors – Dutasteride and Finasteride – in the Presence of Testosterone Singapore Medical Journal · 2021
    2. 5α-Reductase Inhibitors in Men Aged 50 Years or Older with Androgenetic Alopecia: A Retrospective Study Journal of The American Academy of Dermatology · 2020
    3. What Do We Know About 5-Alpha Reductase Inhibitors? Surgical and Cosmetic Dermatology · 2018
    4. 5 Alpha-Reductase Inhibitors: What's New? Current opinion in urology · 2003